Frontlight ResearchEarly access
CompletedEarly phase 1
Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers
Key facts
- Who runs it
- Prince of Songkla University
- Where
- Thailand1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Early phase 1
- People taking part
- 36 people enrolled
- Started
- 1 Mar 2024
- Ended
- 31 May 2024
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Bivalent mRNA SARS-CoV-2 vaccine
- Quardrivalent influenza vaccine
- Record updated
- 4 December 2025
Who can take part
- Age
- 18 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Thai adults aged 18-60 years, who have vaccinated COVID-19 and influenza vaccine more than 6 months
- The subjects are able to and willing to comply with the requirements of the clinical trial program and could complete the 1-month follow-up of the study
- Individuals who are in good health condition at the time of entry into the trial as determined by medical history, physical examination and clinical judgment of the investigator and meet the requirements of immunization
- The subject can provide with informed consent and sign informed consent form (ICF)
Who cannot take part
- Have the history of urticaria 1 year before receiving the investigational vaccine
- Have received blood products within 4 months before injection of investigational vaccines
- Have history of influenza or COVID-19 infection within 6 months
- Have the medical history or family history of convulsion, epilepsy, encephalopathy, and psychosis
- Be allergic to any component of the research vaccines or used to have a history of hypersensitivity or serious reactions to vaccination
- History of Guillain-Barré syndrome
- Have infectious diseases, including HIV and SARS-CoV-2 infection or any symptom of common cold
- Have history of SARS-CoV-2 infection less than 6 months
- Having severe chronic diseases or condition in progress cannot be controlled. For example, poor controlled DM and uncontrolled HT
- Have known underlying diseases of thrombocytopenia or other coagulation disorders (which may cause contraindications for intramuscular injection)
- Have the history of immunosuppressive therapy, cytotoxic therapy, or systemic corticosteroids
- Under anti-tuberculosis treatment
- Not be able to follow the protocol, or not be able to understand the informed consent according to the researcher's judgment, due to various medical, psychological, social, or other conditions
- Women with positive urine pregnancy test, pregnant or breast-feeding, or have a pregnancy plan within six months of after baseline period
- Having needle sickness
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study, a pilot randomized controlled trial, single-blind (outcome assessor), evaluating the immune response (both humoral and cell-mediated) against SARS-CoV-2 and the safety of three different vaccine administration approaches: the SARS-CoV-2 mRNA vaccine alone, the influenza vaccine alone, and the co-administration of both vaccines.
The 3 groups in the trial
- Bivalent mRNA BNT162b2Existing treatment, for comparison
Administering a booster dose of the bivalent mRNA vaccine BNT162b2.
Treatment: Bivalent mRNA SARS-CoV-2 vaccine
- Quardrivalent influenza vaccineTreatment being tested
Administering a VaxigripTetra™
- Co-administrationTreatment being tested
Co-administering bivalent mRNA vaccine BNT162b2 and VaxigripTetra™
Treatment: Bivalent mRNA SARS-CoV-2 vaccine and Quardrivalent influenza vaccine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Immunogenicity to SARS-CoV-2 of Co-administering Bivalent mRNA BNT162b2 Booster and Quadrivalent Influenza Vaccine Among Healthy Volunteers: A Pilot Study
- Record updated
- 4 December 2025